Clinical trials: Anger
Healthy Volunteers, Moderate to Severe Alzheimer Patients
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201.
- Trial name
- NCT01513967
- Testing
- RPh201, botanical drug product
- Where
- 2 sites in Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Regenera Pharma Ltd
Hepatitis B Virus
A Double-Blind Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Participants
This study will assess the safety and tolerability of RO7049389 compared to placebo in single- and multiple-ascending doses in healthy Chinese participants.
- Trial name
- NCT03570658
- Testing
- RO7049389
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Eosinophilic Esophagitis (EoE)
SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects
The principal aim of this study is to obtain safety and tolerability data when AQ280 is administered orally as single and multiple doses to healthy subjects.
- Trial name
- NCT05485779
- Testing
- AQ280
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- AQILION AB
Mild-Moderate Alzheimer's Disease, Healthy Elderly
SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.
The purpose of this study is to assess the safety, drug levels and effects on the body of 1 or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer's Disease or healthy elderly people.
- Trial name
- NCT02036645
- Testing
- MEDI1814 for IV injection, MEDI1814 for Subcutaneous Injection
- Where
- 10 sites in United States
- Volunteers
- 77 people
- Sponsor
- AstraZeneca
Alzheimer's Disease, Healthy Non-elderly and Elderly Adults
Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
This is a Phase 1/2a, multi-center, placebo-controlled, double-blinded, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose of AL001.
- Trial name
- "MAD" (NCT05363293)
- Testing
- AL001
- Where
- 2 sites in United States, Canada
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Alzamend Neuro, Inc.
Healthy
MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects
A study in healthy subjects to assess the safety, tolerability, and pharmacokinetics of N91115.
- Trial name
- SNO2 (NCT02013388)
- Testing
- N91115
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Nivalis Therapeutics, Inc.
Chronic Hypoparathyroidism
AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism
This study is investigating the safety, tolerability, pharmacodynamics and pharmacokinetics of AZP-3601 following single and repeated administration in both healthy volunteers and patients with chronic hypoparathyroidism (cHP)…
- Trial name
- NCT05239221
- Testing
- AZP-3601
- Where
- 2 sites in Hungary, Netherlands
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Cocaine Use Disorder, Substance Use Disorders
Multiple Ascending Dose Study of TMP-301 in Healthy Subjects
A PHASE 1, RANDOMIZED, PLACEBO CONTROLLED, MULTIPLE ASCENDING DOSE (MAD) STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TMP-301 IN HEALTHY SUBJECTS.
- Conditions
- Cocaine Use Disorder, Substance Use Disorders, Healthy Volunteers
- Trial name
- NCT06025396
- Testing
- Cohort 1 - TMP-301, Cohort 2 - TMP-301, Cohort 3 - TMP-301
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tempero Bio, Inc.
COPD, Healthy Subjects
To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients
This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD7624 in healthy subjects and patients with chronic obstructive pulmonary disease.
- Trial name
- NCT01817855
- Testing
- AZD7624
- Where
- United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Male Subjects, Cardiovascular Disease
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects
This is a phase I, randomised, single-blind, placebo-controlled, first-in-human (FIH) single and multiple ascending dose study consisting of two parts (Part A [SAD] and Part B [MAD]) to assess the safety, tolerability…
- Trial name
- NCT02632526
- Testing
- AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A), AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A), AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Lung Cancer, Mesothelioma
CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD)
The purpose of this study is to evaluate the safety, and tissue effect of the CryoSpray Ablation(TM) System (CryoSpray Ablation(TM), "CSA" or "cryospray therapy") at multiple centers to treat malignant airway disease in the lung…
- Trial name
- ICEtheMAD (NCT00748085)
- Testing
- CryoSpray Ablation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- CSA Medical, Inc.
Healthy Adult Participants
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects
ARN-75039 is proposed for the treatment of subjects with LASV infection, Lassa hemorrhagic fever, a potentially fatal human disease associated with Lassa viruses, with the most significant unmet medical need.
- Trial name
- NCT05735249
- Testing
- ARN-75039 oral capsules
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Arisan Therapeutics, Inc.
HIV Infections
Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study
This is a phase 1, 2-part, double-blind (sponsor-unblinded), randomized, placebo-controlled, FTIH study, that includes both single-ascending and multiple-ascending dose phase to assess the safety, tolerability, and…
- Trial name
- NCT03984812
- Testing
- GSK3732394
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Cerebrovascular Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)
A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers
Study BT200-01 is a first in human (FIH) study in male and female normal human volunteers (NHVs) that uses an Integrated Protocol Design.
- Conditions
- Cerebrovascular Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis), Intracranial Arteriosclerosis
- Trial name
- NCT04103034
- Testing
- BT200, Desmopressin
- Where
- Austria
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Band Therapeutics
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.
- Trial name
- AMARONE (NCT05919693)
- Testing
- EYE103
- Where
- 32 sites in United States, Argentina and 2 more
- Volunteers
- 33 people
- Sponsor
- EyeBiotech Ltd.
Allergic Bronchopulmonary Aspergillosis
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
The primary safety objectives were: Part 1: To determine the safety and tolerability of single doses of ZP-059 in healthy subjects Part 2: To determine the safety and tolerability of multiple doses of ZP-059 in subjects with mild…
- Trial name
- NCT04229303
- Testing
- Voriconazole inhaled, oral voriconazole
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Zambon SpA
Healthy Volunteers
AZD8108 SAD/MAD in Healthy Volunteers
This is a randomized, double-blind, placebo-controlled study of single and multiple ascending dosage levels of AZD8108 in healthy volunteers.
- Trial name
- AZD8108 (NCT02248818)
- Testing
- AZD8108
- Where
- United States
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hepatitis B
First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects
This study is a Phase 1, randomized, double-blind (Sponsor unblinded), placebo controlled, dose escalation study to determine the safety, tolerability and pharmacokinetics (PK) profile of GSK3389404 as single (Part 1) and…
- Trial name
- NCT02647281
- Testing
- GSK3389404
- Where
- 2 sites in United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Safety and Tolerability
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
This was a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered GB1211 will be evaluated in healthy adult subjects and adult…
- Trial name
- NCT03809052
- Testing
- GB1211
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Galecto Biotech AB
Healthy Volunteers
A Combined SAD and MAD Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of IFB-088
This is the first study of single and multiple doses of IFB-088 in human subjects. The current study is designed to assess in the first part, the safety, tolerability, plasma and urine pharmacokinetics (PK) of single oral doses…
- Trial name
- NCT03610334
- Testing
- IFB-088 (2.5-60.0mg) oral capsule, IFB-088 (15.0-50.0mg) oral capsule
- Where
- 2 sites in France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- InFlectis BioScience